Xbrane Biopharma AB (ST:XBRANE) — Stock Price

Skr10.15 SEK
▲ 1.50% today

Xbrane Biopharma AB (ST:XBRANE) is currently trading at Skr10.15 SEK, up 1.50% today. Over the past 52 weeks, shares have ranged between Skr0.24 and Skr23.30. This page tracks Xbrane Biopharma AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see XBRANE company net worth.

Xbrane Biopharma AB (XBRANE) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Xbrane Biopharma AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.

Xbrane Biopharma AB Income Statement — Revenue, Profit & Earnings by Year

Xbrane Biopharma AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Skr152.35 Million Skr198.70 Million Skr238.73 Million Skr57.62 Million Skr11.53 Million
Cost of Revenue Skr77.41 Million Skr18.23 Million Skr203.34 Million Skr16.58 Million Skr12.22 Million
Gross Profit Skr74.94 Million Skr180.47 Million Skr35.39 Million Skr41.04 Million Skr-684.00K
Research & Development Skr76.82 Million Skr312.89 Million Skr305.78 Million Skr199.65 Million Skr160.62 Million
SG&A Skr43.82 Million Skr40.11 Million Skr40.03 Million Skr31.54 Million Skr31.39 Million
Total Operating Expenses Skr106.04 Million Skr398.40 Million Skr357.55 Million Skr210.27 Million Skr191.93 Million
Operating Income Skr-31.10 Million Skr-217.92 Million Skr-310.43 Million Skr-166.22 Million Skr-180.40 Million
EBITDA Skr-16.50 Million Skr-181.97 Million Skr-282.03 Million Skr-149.34 Million Skr-167.59 Million
EBIT Skr-31.10 Million Skr-217.92 Million Skr-303.47 Million Skr-165.92 Million Skr-179.81 Million
Interest Expense Skr15.69 Million Skr36.02 Million Skr2.27 Million Skr2.58 Million Skr2.64 Million
Income Before Tax Skr-43.93 Million Skr-253.43 Million Skr-322.03 Million Skr-168.51 Million Skr-183.23 Million
Income Tax Expense Skr2.23 Million Skr11.59 Million Skr66.14 Million Skr3.71 Million Skr7.79 Million
Net Income Skr127.24 Million Skr-266.22 Million Skr-388.17 Million Skr-172.23 Million Skr-191.01 Million

Xbrane Biopharma AB Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Xbrane Biopharma AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Skr671.62 Million Skr842.43 Million Skr653.51 Million Skr690.51 Million Skr688.43 Million
Total Current Assets Skr375.13 Million Skr605.90 Million Skr461.69 Million Skr513.52 Million Skr561.01 Million
Cash & Equivalents — — — — —
Short-term Investments — — — — —
Net Receivables Skr12.30 Million Skr232.68 Million Skr71.18 Million Skr47.46 Million Skr50.25 Million
Inventory Skr194.27 Million Skr246.90 Million Skr106.86 Million Skr50.26 Million Skr215.57 Million
Property, Plant & Equipment Skr36.00K Skr64.90 Million Skr88.20 Million Skr71.05 Million Skr73.80 Million
Goodwill Skr0.00 Skr0.00 Skr0.00 Skr0.00 Skr0.00
Total Liabilities Skr110.97 Million Skr633.89 Million Skr482.17 Million Skr265.63 Million Skr256.69 Million
Total Current Liabilities Skr52.66 Million Skr537.94 Million Skr326.56 Million Skr236.57 Million Skr219.67 Million
Long-term Debt Skr58.31 Million Skr66.37 Million Skr112.90 Million Skr0.00 —
Net Debt Skr-28.28 Million Skr67.39 Million Skr166.08 Million Skr-155.77 Million Skr-250.80 Million
Total Stockholder Equity Skr560.65 Million Skr208.54 Million Skr171.34 Million Skr424.89 Million Skr431.74 Million
Retained Earnings Skr-837.61 Million Skr-1.54 Billion Skr-1.27 Billion Skr-885.83 Million Skr-713.31 Million

Xbrane Biopharma AB Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Xbrane Biopharma AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Skr-250.69 Million Skr-133.73 Million Skr-406.68 Million Skr-193.92 Million Skr-219.61 Million
Capital Expenditures Skr139.64 Million Skr52.25 Million Skr16.77 Million Skr60.12 Million Skr77.35 Million
Free Cash Flow Skr-250.69 Million Skr-185.97 Million Skr-423.45 Million Skr-254.04 Million Skr-296.96 Million
Investing Cash Flow Skr-37.14 Million Skr-52.25 Million Skr-16.77 Million Skr-60.12 Million Skr-77.35 Million
Financing Cash Flow Skr255.60 Million Skr243.62 Million Skr298.70 Million Skr148.86 Million Skr349.37 Million
Dividends Paid — — — — —
Stock-Based Compensation — — Skr1.83 Million Skr8.85 Million Skr4.55 Million
Depreciation Skr14.60 Million Skr35.95 Million Skr21.43 Million Skr16.58 Million Skr13.00 Million
Change in Cash Skr-37.74 Million Skr58.93 Million Skr-128.59 Million Skr-101.19 Million Skr52.04 Million

Xbrane Biopharma AB Earnings History — EPS Actual vs. Analyst Estimates

Track Xbrane Biopharma AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 06, 2026 -0.63 — —
Feb 19, 2026 -1.27 -1.49 +14.77%
Oct 24, 2025 -1.17 1.42 -182.39%
Aug 26, 2025 -0.52 16.91 -103.08%
May 08, 2025 1.25 -3.47 +136.02%
Feb 20, 2025 -3.75 5.10 -173.53%
Oct 24, 2024 -3.66 -3.62 -1.11%
Aug 28, 2024 -0.05 -0.04 -25.00%